Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-031052
Date:2021-05-05
Issuer: PMV PHARMACEUTICALS, INC. (PMVP)
Original Submission Date:

Reporting Person:

SCHROEDER THILO
C/O PMV PHARMACEUTICALS, INC.
8 CLARKE DRIVE, SUITE 3 CRANBURY, NJ 08512

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-05-05 S 600 d $35.64 2,106,201 indirect f3
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 shares were sold pursuant to a rule 10b5-1 trading plan.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $35.60 to35.68 inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities andexchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth inthis footnote.
f3 the shares are held of record by nextech v oncology s.c.s., sicav-sif. the reporting person is a partner at nextech invest ag and in the investment committee of nextech invest ag, with significant influence over nextech v oncology s.c.s., sicav-sif in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. the reporting person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

Elevate your investments